Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease

S J Charles, J J Gray

Abstract
Forty isolates of herpes simplex virus (HSV) obtained from ocular herpetic infections were assayed for their sensitivity to five antiviral agents. There were wide ranges of sensitivity to foscarnet, idoxuridine, and vidarabine, but the majority were sensitive to acyclovir and ganciclovir. Reduced sensitivity to acyclovir was seen in four isolates, all of which were from primary infections acquired in the community and without a previous history of treatment with antiviral drugs.

With the widespread use of antiviral drugs in herpetic infections the development of resistant herpes simplex virus (HSV) strains must be monitored. In-vitro virus resistance to acyclovir (ACV) may be selected for by passage in cell culture in the presence of the drug. Resistant strains arise from alterations at one or both of the gene loci coding for virus-specific enzymes thymidine kinase (TK) and DNA polymerase (DNA-pol) and may emerge during treatment with ACV.

In a recent study of all HSV isolates in this hospital it was noted that isolates obtained from ocular infections had a reduced sensitivity to ACV compared with infections at other sites.

The present study aimed to evaluate the sensitivity of HSV isolates to a range of antiviral drugs, including ACV, in the entire population of patients presenting to the Ophthalmology Clinic with herpetic eye disease, together with isolates from ocular infections sent to the virology laboratory from general practitioners. The active concentrations of antiviral drugs at the site of ocular infections are not well known, and so antiviral resistance should be considered relative to sensitive strains. It seems reasonable to consider that isolates showing a greater than 10-fold increase in the inhibitory concentration of the drug above the mean value for sensitive isolates may be significant in terms of reduced effectiveness of therapy.

Materials and methods

Virus isolation
Swabs were collected in virus transport medium (2 ml Hanks's buffered saline with 1% bovine albumin) from lesions of patients with suspected HSV infection of the eye. A volume of 100 μl was inoculated into cultures of human amnion, HEp2, and MRC-5 cells, which were then rolled for 21 days at 37°C. Cultures showing a cytopathic effect characteristic of HSV were stored at −20°C. Serotyping of the HSV isolates was performed by direct immunofluorescence (Boots-Celltech Diagnostics Ltd.).

Controls
Isolates of HSV designated DM 21 (a TK-deletion mutant), TP 2-5 (a DNA-pol mutant), and R9C2 (a TK and DNA-pol mutant), all resistant to ACV, were grown in cultures of human amnion cells for use as controls, as was a strain, sensitive to ACV, designated SC16.

Antiviral agents
Five agents all reported to be active against HSV were used: acyclovir, ganciclovir, foscarnet, idoxuridine, and vidarabine.

Dye uptake test
Virus growing in cultures of cells reduces the uptake of the vital stain neutral red by the cells. When the assay is performed in microtitre plates, the dye can be eluted and its concentration measured colorimetrically. Isolates of virus were screened for susceptibility to concentrations of each antiviral agent from 0-05 μg/ml to 100 μg/ml. They were thawed and diluted 1 in 10 and 1 in 100 in a suspension of vero cells (100 000 cells/ml) in growth medium (BSS 199, 5% FBS), 100 μl of each dilution was placed in alternate rows on the microtitre plate and an equal volume of antiviral drug, at varying concentrations, was then added to each well. Cell controls and virus controls were included with each isolate, and the plates were incubated at 37°C in an atmosphere of 5% carbon dioxide for three days.

After incubation the medium was aspirated from the wells and replaced with 50 μl of the vital stain neutral red (0-15% in phosphate buffered saline (PBS) at pH 6-5). The plates were then incubated for one hour at 37°C, after which the stain was removed by aspiration and the wells washed twice with PBS pH 6-5. The dye was rendered soluble by addition of 100 μl phosphate ethanol buffer (PBS pH 4-5 containing 10% ethanol). The optical density was read at 510 nm. End points were taken as the lowest concentration of antiviral agent to inhibit growth of the virus by 50% (IC50) when compared with
occlusion was 0·32 μg/ml (0·025 μg/ml after excluding the isolates with IC50 10·00 μg/ml).

Discussion
This study, using a dye uptake assay, has shown that the majority of HSV isolates from patients with herpetic eye disease are particularly sensitive in vitro to ACV. A total of 87·5% of isolates were sensitive to ACV with IC50 of less than 0·05 μg/ml. Isolates were also sensitive to ganciclovir in a similar distribution, as would be expected from its similar mode of action, but there was a wider distribution of sensitivities to the other antiviral agents. A total of three out of 40 (7·5%) isolates had reduced sensitivity to ACV and one out of 40 (2·5%) was resistant.

It might be expected that resistant isolates would be seen in patients with a previous history of treatment with ACV. However, the isolate with an IC50 of 10·00 μg/ml ACV was obtained from a 12-year-old asthmatic boy suffering from a primary attack of HSV blepharitis at the time of a hospital admission with pneumonia. No causative organism for the pneumonia was isolated, and he responded to intravenous antibiotics. He was not known to have been in contact with active HSV infection, though his father had had herpes labialis many years previously (and had never received ACV). This may indicate that resistant strains of HSV exist in the general population, though we cannot exclude the possibility that a resistant strain was selected during virus isolation. This resistant strain was sensitive to IDU, foscarnet, and vidarabine.

Of the three isolates with significantly reduced ACV sensitivities (IC50 0·5 μg/ml) none had any history of recurrent HSV infection or previous treatment with ACV. One was a case of follicular conjunctivitis associated with a first attack of herpes labialis and the other two were first dendritic ulcers. All resolved on treatment but one recurred. The isolate recovered from the recurrent infection was sensitive to ACV (IC50 <0·05 μg/ml). The sensitive strain may have established the latent infection before the resistant strain emerged or was more able to establish a latent infection, as has been previously described.12

It is difficult to assess the clinical importance of infection with strains of HSV showing altered sensitivity to ACV when the drug is applied topically. After topical administration concentrations of ACV measured in tears varied from 0·07 μg/ml to 465 μg/ml13 and in aqeous was around 1·7 μg/ml.14 Thus it seems that drug concentrations sufficient to inhibit the virus are available at the site of infection even though the strain may have a significantly reduced sensitivity to ACV. The strain resistant to ACV and ganciclovir was sensitive to foscarnet, IDU, and vidarabine, so that a therapeutic alternative, if required, is available.

It thus seems that strains of HSV with reduced sensitivity to ACV exist in the population of patients with herpetic eye disease, but, because of the high ACV levels achieved when applied topically, they respond well to therapy. Virus from subsequent recurrences of HSV disease in such cases may be fully sensitive to ACV.
Figure 2: Distribution of acyclovir IC\textsubscript{50} values in HSV isolates in patients with ocular infection. IC\textsubscript{50} values for control strains (see text) are also shown.

Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease.
S. J. Charles and J. J. Gray

doi: 10.1136/bjo.74.5.286

Updated information and services can be found at: http://bjo.bmj.com/content/74/5/286

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/